Last reviewed · How we verify
Antiplatelet Agents
Antiplatelet agents inhibit platelet aggregation and clot formation by blocking platelet activation pathways.
Antiplatelet agents inhibit platelet aggregation and clot formation by blocking platelet activation pathways. Used for Acute coronary syndrome, Secondary prevention of myocardial infarction, Ischemic stroke prevention.
At a glance
| Generic name | Antiplatelet Agents |
|---|---|
| Also known as | Aspirin, Clopidogrel, aspirin, clopidogrel, lysine acetylsalicylate or equivalent |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Antiplatelet agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Antiplatelet agents work through various mechanisms including inhibition of cyclooxygenase (aspirin), adenosine diphosphate receptor antagonism (clopidogrel, ticlopidine), or phosphodiesterase inhibition (dipyridamole). These drugs prevent platelets from clumping together and forming thrombi, reducing the risk of thrombotic cardiovascular events.
Approved indications
- Acute coronary syndrome
- Secondary prevention of myocardial infarction
- Ischemic stroke prevention
- Peripheral arterial disease
Common side effects
- Bleeding
- Gastrointestinal upset
- Dyspepsia
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (NA)
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (PHASE3)
- Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion (NA)
- Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiplatelet Agents CI brief — competitive landscape report
- Antiplatelet Agents updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI